Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis open-label extension after ATTRibute-CM
2020-005643-22Phase 3Active
- Sponsor
- Eidos Therapeutics
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Eidos Therapeutics. Primary endpoints: Treatment-emergent serious adverse events, Adverse events and 5 more. Started Aug 2021; status: active.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2020-005643-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005643-22.